Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model

Journal of the National Cancer Institute

Volumn 90, Issue 15, 1998, Pages 1146-1154

  Smith, Janet B ^a   Wickstrom, Eric ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ACTIN; MYC PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER TRANSPLANTATION; CODON; CONTROLLED STUDY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; REMISSION;

EID: 0032486759     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.15.1146     Document Type: Article

References (39)

1. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-48.
2. Magrath I. Molecular basis of lymphomagenesis. Cancer Res 1992;52(19 Suppl):5529s-5540s.
3. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-95.
4. Wickstrom E, editor. Prospects for antisense nucleic acid therapy of cancer and AIDS. New York: Wiley-Liss, 1991.
5. Agrawal S, editor. Antisense therapeutics. Totowa (NJ): Humana, 1996.
6. Wickstrom E, editor. Clinical trials of genetic therapy with antisense DNA and DNA vectors. New York: Marcel Dekker, 1998.
7. Magrath IT. Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas. Ann Oncol 1994;5 Suppl 1:67-70.
8. Webb A, Cunningham D, Cotter F, Clarke P, di Stefano F, Ross P, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
9. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987;328:445-9.
10. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A 1988; 85:1028-32.
11. McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Shiramizu BT, et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990;335:808-11.
12. Bacon TA, Wickstrom E. Walking along human c-myc mRNA with antisense oligonucleotides: maximum efficacy at the 5′ cap region. Oncogene Res 1991;6:13-9.
13. Shi Y, Hutchinson HG, Hall DJ, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 1993;88:1190-5.
14. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, et al. Oligonucleotide N3′→P5′ phosphoramidates as antisense agents. Nucleic Acids Res 1996;24:1508-14.
15. Wickstrom E, Bacon TA, Wickstrom EL. Down-regulation of c-MYC antigen expression in lymphocytes of Eμ-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 1992;52: 6741-5.
16. Huang Y, Snyder R, Kligshteyn M, Wickstrom E. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol Med 1995;1: 647-58.
17. Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B. Antileukemia effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A 1997;94:3966-71.
18. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
19. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991;147: 1759-64.
20. Messina JP, Gilkeson GS, Pisetsky DS. The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol 1993;147:148-57.
21. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev 1996;6:133-9.
22. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879-83.
23. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
24. Pieles U, Zurcher W, Schar M, Moser HE. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Res 1993;21:3191-6.
25. Iyer RP, Phillips LR, Egan W, Regan JB, Beaucage SL. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J Org Chem 1990;55:4693-9.
26. Daniel W.W. Biostatistics: a foundation for analysis in the health sciences. 6th ed. New York: Wiley, 1995.
27. Baker AR, Weber JS. Treatment of malignant ascites. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Vol 2, 4th ed. Philadelphia: Lippincott, 1993:2245-61.
28. Seeley RR, Stephens TD, Tate P. The circulatory system: internal transport and defense. In: Smith JM, editor. Essentials of anatomy and physiology. New York: Mosby-Year, 1996:504-18.
29. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996;14:376-87.
30. Gray GD, Townsend R, Hayasaka H, Korngold R, Wickstrom E. Immune cell involvement in anti-c-myc DNA prevention of tumor formation in a mouse model of Burkitt's lymphoma. Nucleosides Nucleotides 1997;16: 1727-30.
31. Ho PT, Ishiguro K, Wickstrom E, Sartorelli AC. Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev 1991;1: 329-42.
32. Yaswen P, Stampfer MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993;3:67-77.
33. Burgess TL, Fisher EF, Ross SL, Breads JV, Qian YX, Bayewitch LA, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 1995;92:4051-5.
34. Basu S, Wickstrom E. Temperature and salt dependence of higher order structure formation by antisense c-myc and c-myb phosphorothioate oligodeoxyribonucleotides containing tetraguanylate tracts. Nucleic Acids Res 1997;25:1327-32.
35. Jain RK. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1997;4: 1-23.
36. Yi AK, Klinman DM, Martin TL, Matson S, Krieg AM. Rapid immune actuation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 1996; 157:5394-402.
37. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996;156:4570-5.
38. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988;167: 353-71.
39. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.